{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T21:59:18Z","timestamp":1768341558616,"version":"3.49.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:00:00Z","timestamp":1428624000000},"content-version":"vor","delay-in-days":1013,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"German Research Council","award":["JU 417\/2-2 and SFB Transregio 37"],"award-info":[{"award-number":["JU 417\/2-2 and SFB Transregio 37"]}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.bbmt.2011.12.522","type":"journal-article","created":{"date-parts":[[2011,12,16]],"date-time":"2011-12-16T11:10:53Z","timestamp":1324033853000},"page":"1061-1068","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Everolimus in Combination with Cyclosporin A as Pre- and Posttransplantation Immunosuppressive Therapy in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation"],"prefix":"10.1016","volume":"18","author":[{"given":"Christian","family":"Junghanss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Rathsack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"Wacke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volker","family":"Weirich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heike","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"Drewelow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Altmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathias","family":"Freund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Lange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2011.12.522_bib1","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1097\/01.TP.0000140486.97461.49","article-title":"Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study","volume":"78","author":"Nashan","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2011.12.522_bib2","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1056\/NEJMoa022171","article-title":"Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients","volume":"349","author":"Eisen","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2011.12.522_bib3","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.healun.2005.12.001","article-title":"Everolimus in pulmonary transplantation: pharmacokinetics and exposure-response relationships","volume":"25","author":"Kovarik","year":"2006","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.bbmt.2011.12.522_bib4","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1111\/j.1600-6143.2005.01063.x","article-title":"Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients","volume":"5","author":"V\u00edtko","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.bbmt.2011.12.522_bib5","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1097\/01.tp.0000290686.68910.bd","article-title":"A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus","volume":"84","author":"Hill","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2011.12.522_bib6","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.bbmt.2008.11.004","article-title":"Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial","volume":"15","author":"Platzbecker","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.12.522_bib7","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1007\/BF00352386","article-title":"Identification and characterization of a highly polymorphic microsatellite marker within the canine MHC class I region","volume":"6","author":"Burnett","year":"1995","journal-title":"Mamm Genome"},{"key":"10.1016\/j.bbmt.2011.12.522_bib8","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1097\/00007890-199609270-00032","article-title":"Histocompatibility testing of dog families with highly polymorphic microsatellite markers","volume":"62","author":"Wagner","year":"1996","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2011.12.522_bib9","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1023\/B:VERC.0000047486.01458.c5","article-title":"Canine haematopoietic chimerism analyses by semiquantitative fluorescence detection of variable number of tandem repeat polymorphism","volume":"29","author":"Hilgendorf","year":"2005","journal-title":"Vet Res Commun"},{"key":"10.1016\/j.bbmt.2011.12.522_bib10","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1365-2125.2005.02434.x","article-title":"Pharmacokinetic interaction between verapamil and everolimus in healthy subjects","volume":"60","author":"Kovarik","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bbmt.2011.12.522_bib11","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1177\/0091270005275368","article-title":"Blood concentrations of everolimus are markedly increased by ketoconazole","volume":"45","author":"Kovarik","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.bbmt.2011.12.522_bib12","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1016\/j.transproceed.2008.08.111","article-title":"Preliminary experience with conversion from calcineurin inhibitors to everolimus in cardiac transplantation maintenance therapy","volume":"40","author":"S\u00e1nchez-Brotons","year":"2008","journal-title":"Transplant Proc"},{"key":"10.1016\/j.bbmt.2011.12.522_bib13","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/bdd.524","article-title":"Everolimus drug interactions: application of a classification system for clinical decision making","volume":"27","author":"Kovarik","year":"2006","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.bbmt.2011.12.522_bib14","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1016\/j.transproceed.2006.10.092","article-title":"Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus","volume":"38","author":"Kovarik","year":"2006","journal-title":"Transplant Proc"},{"key":"10.1016\/j.bbmt.2011.12.522_bib15","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/FTD.0b013e318161a335","article-title":"Everolimus exposure in cardiac transplant recipients is influenced by concomitant calcineurin inhibitor","volume":"30","author":"Brandhorst","year":"2008","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.bbmt.2011.12.522_bib16","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1093\/ndt\/gfh322","article-title":"Tolerability and steady-state pharmacokinetics of everolimus in maintenance renal transplant patients","volume":"19","author":"Budde","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.bbmt.2011.12.522_bib17","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1016\/j.transproceed.2007.09.008","article-title":"Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy","volume":"39","author":"Chapman","year":"2007","journal-title":"Transpl Proc"},{"key":"10.1016\/j.bbmt.2011.12.522_bib18","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1067\/mcp.2001.112969","article-title":"Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine","volume":"69","author":"Kovarik","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bbmt.2011.12.522_bib19","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/sj.bmt.1705958","article-title":"Pharmacokinetics of oral mycophenolate mofetil in combination with CsA in dogs after nonmyeloablative allogeneic hematopoietic stem cell transplantation","volume":"41","author":"Lange","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.12.522_bib20","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1177\/0091270005277196","article-title":"Influence of everolimus on steady-state pharmacokinetics of cyclosporine in maintenance renal transplant patients","volume":"45","author":"Budde","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.bbmt.2011.12.522_bib21","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1046\/j.1365-2125.2000.00293.x","article-title":"Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RAD","volume":"50","author":"Kirchner","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bbmt.2011.12.522_bib22","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1182\/blood.V89.8.3048","article-title":"Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation","volume":"89","author":"Storb","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.12.522_bib23","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.bbmt.2006.10.031","article-title":"CD154 blockade and donor-specific transfusions in DLA-identical marrow transplantation in dogs conditioned with 1-Gy total body irradiation","volume":"13","author":"Jochum","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.12.522_bib24","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1083-8791(03)00148-4","article-title":"Postgrafting immunosuppression with sirolimus and cyclosporine facilitates stable mixed hematopoietic chimerism in dogs given sublethal total body irradiation before marrow transplantation from DLA-identical littermates","volume":"9","author":"Hogan","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.12.522_bib25","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(10)62318-5","article-title":"Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial","volume":"377","author":"Budde","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2011.12.522_bib26","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.healun.2007.02.008","article-title":"Observational study with everolimus (Certican) in combination with low-dose cyclosporine in de novo heart transplant recipients","volume":"26","author":"Lehmkuhl","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.bbmt.2011.12.522_bib27","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1002\/lt.20707","article-title":"Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results","volume":"12","author":"Levy","year":"2006","journal-title":"Liver Transpl"},{"key":"10.1016\/j.bbmt.2011.12.522_bib28","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1097\/01.TP.0000141094.34903.54","article-title":"Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de\u00a0novo renal transplant recipients","volume":"78","author":"V\u00edtko","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2011.12.522_bib29","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.bbmt.2008.05.004","article-title":"Sirolimus in combination with tacrolimus in allogeneic stem cell transplantation\u2014timing and conditioning regimen may be crucial","volume":"14","author":"Wolff","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.12.522_bib30","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.bbmt.2008.02.009","article-title":"Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors","volume":"14","author":"Furlong","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.12.522_bib31","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.exphem.2008.09.011","article-title":"Investigation of immunological approaches to enhance engraftment in a 1 Gy TBI canine hematopoietic stem cell transplantation model","volume":"37","author":"Lange","year":"2009","journal-title":"Exp Hematol"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879111010846?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879111010846?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:41:22Z","timestamp":1761057682000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879111010846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S1083879111010846"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2011.12.522","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Everolimus in Combination with Cyclosporin A as Pre- and Posttransplantation Immunosuppressive Therapy in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2011.12.522","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}